Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines

This Viewpoint discusses use of skinny labeling to reduce the price of brand-name drugs, impediments to timely generic market entry and affordability, and inducement liability that causes marketing uncertainty.

Corresponding Author: S. Sean Tu, PhD, JD, University of Alabama School of Law, 101 Paul W. Bryant Dr E, Tuscaloosa, AL 35487 (shinetu@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.